Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 45 OC6.9 | DOI: 10.1530/endoabs.45.OC6.9

BSPED2016 Oral Communications Oral Communications 6- Endocrine (9 abstracts)

A single centre experience of Differences/Disorders in Sex Development (DSD) over 20 years

Elim Man 1, , GOSH DSD MDT 2 & John Achermann 1,

1UCL GOS Institute of Child Health, London, UK; 2Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Introduction: Differences/Disorders in Sex Development (DSD) represent a diverse range of conditions that present at various stages of life. A multidisciplinary team (MDT) approach is required to reach a specific diagnosis and management plan, but few large single centre studies of the range and prevalence of diagnoses have been undertaken.

Method: Medical records of all children with DSD discussed at a single MDT between 1-Jan-1996 and 31-Dec-2015 (n=580) were retrospectively reviewed to evaluate the referral patterns and diagnoses; clinical features, biochemical data and genetic analyses were considered.

Results: A total of 271 (1996–2005) and 309 (2006–2015) children were discussed in two respective decades. The relative proportions of DSD categories were similar across two decades (Sex chromosome DSD [SCDSD]: 8.1%/12.0%; 46,XX DSD: 29.2%/25.9%; 46,XY DSD: 62.7%/62.1% in 1996–2005/2006–2015 respectively). Overall, 300/580 children were discussed in their first year of life, with an increase in the number and proportion of children referred earlier in the second decade (2006–2015) (185 versus 115; 59.8% versus 42.4%). Specific diagnoses among children discussed in their first year of life for SCDSD (n=30) included 45,X/46,XY and X variants (n=21), 47,XXY variants and children with 46,XX/46,XY chimerism (n=3). Most children with 46,XX DSD (n=87) had congenital adrenal hyperplasia (CAH) (n=58), the rest having ovotesticular DSD (n=4), isolated clitoromegaly or cloacal anomalies. Among 46,XY DSD (n=183), specific molecular diagnoses were reached in 39 children (including disease-causing variants in SF1, WT1, SOX9, STAR, HSD3B2, HSD17B3, AR, and SRD5A2). Most (n=112) of the others were 46,XY boys with severe hypospadias and often associated features including intra-uterine growth restriction, and/or renal, cardiac or syndromic anomalies. Relatively few 46,XY females presented in infancy (30/109), but molecular diagnosis was reached in 20/23 46,XY females born within the last 10 years.

Conclusion: Children with a heterogeneous range of conditions were referred to the DSD MDT at our centre. Understanding the relative prevalence of those conditions is very valuable. Molecular analysis is useful in reaching a specific diagnosis and directing management, but the underlying pathophysiology in most 46,XY children with severe hypospadias currently remains unknown, and could include genetic, epigenetic, and/or environmental factors.

Volume 45

44th Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.